CONFERENCES

      Food and Drug Law Institute Conference

      The Food and Drug Law Institute (FDLI) is a nonprofit membership organization that offers education, training, publications, and professional engagement opportunities in the field of food and drug law. Among others, FDLI hosts conferences that explore the latest developments in tobacco and nicotine regulatory science, with topics ranging from product safety to consumer behavior. Thesw conferences are aimed at researchers, industry professionals, and policymakers involved in the study and regulation of tobacco and nicotine products, and provide a forum for sharing knowledge and collaborating on new approaches to tobacco control.

      Tobacco and Nicotine Product Regulatory Science Symposium (2023)

      Date

      Mar 30, 2023

      Location

      Washington D.C., USA

      Online

      The Symposium will provides a forum for diverse stakeholders to share scientific studies and research from a wide range of disciplines. Ths year's presentations focus on studies and research that are either conducted for or contribute to the U.S. regulatory process, which is established by the Tobacco Control Act and administered by the U.S. Food and Drug Administration’s Center for Tobacco Products (CTP).

      FDLI Annual Conference 2016

      Date

      May 05, 2016 - May 06, 2016

      Location

      Washington DC, USA

      The 2016 FDLI Annual Conference will cover legal, regulatory, policy, and economic issues spanning the broad range of FDA’s authority by bringing together experts from the federal government, industry, the private bar, patient and consumer advocates, consulting organizations, and academia.

      See related presentations

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.